Skip to main content

Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain

Buy Article:

$51.00 plus tax (Refund Policy)

Abstract:

Please cite this paper as: Al-Azemi M, Jones G, Sirkeci F, Walters S, Houdmont M, Ledger W. Immediate and delayed add-back hormonal replacement therapy during ultra long GnRH agonist treatment of chronic cyclical pelvic pain. BJOG 2009; DOI: 10.1111/j.1471-0528.2009.02319.x. Objective 

To assess the safety and efficacy of long-term use of long-acting GnRH agonist in women with chronic cyclical pelvic pain using immediate versus delayed add-back hormonal replacement therapy (HRT). Design 

A prospective randomised trial. Setting 

Reproductive and Developmental Medicine, Academic Unit, University Teaching Hospital and NHS Hospitals. Population 

Thirty-eight premenopausal women with chronic cyclical pelvic pain were recruited. Methods 

Women were given Zoladex 10.8 mg over 18 months and randomised to receive HRT (tibolone 2.5 mg) either immediately or after 6 months. Follow up was 12-month post-treatment. Main outcome measures 

Bone mineral density at 6 months, the end of treatment (18 months), and 12 months later, pain and quality of life. Results 

Women treated with immediate HRT add-back showed less bone mineral density loss at 6 months and less vasomotor symptoms compared with those who had delayed HRT add-back treatment. Long-term follow up showed both groups experienced equivalent bone mineral density loss. Pain and health-related quality-of-life assessment showed improvement in both groups but there was evidence of a return to baseline levels after ending treatment. Conclusion 

Long-term use of GnRH agonist plus immediate add-back HRT is a safe and acceptable approach to intractable cyclical pelvic pain. Given the delay in reactivation of the hypothalamo-pituitary-ovarian axis after long-term suppression, an intermittent dose regime with GnRH agonist might warrant investigation.

Keywords: Add-back therapy; GnRH agonist; bone mineral density; chronic pelvic pain; endometriosis

Document Type: Research Article

DOI: https://doi.org/10.1111/j.1471-0528.2009.02319.x

Publication date: 2009-11-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more